

Number ID	Review Info	Specific Comments To Authors
02445209		

Thanks very much for your kind reviews and comments. Changes have been made as detailed below.

Dear author, I have a few comments on your manuscript: - If you have abbreviations in Abstract, they should be explained in Abstract (in addition to the main text).

Done, and highlighted in yellow.

- In Introduction, you write, that "there is still no definitive medication treatment for the core features of autism". Do you think we will ever have any such medication? In my opinion, autism is a neurodevelopmental disorder with many DNA defects (SNPs, CNVs etc.), the brain is already damaged in utero, we will never have any medication for the core features of autism. You can state your opinion on this in Discussion.

This is a very good point: see 1st paragraph in **Discussion**, added: ***Regarding future drug treatments for core ASD symptoms, it may not be possible for one drug to target and treat all of the many subtypes of ASD, given the many genetic and other causes.***

- In your manuscript, you quote many pharmacological studies in ASD. You should explain in which way you chose these studies. The reviewer

See first sentence under **Discussion**: added: ***Studies included followed a broad and thorough literature review of pharmacotherapy in ASD, in order to provide a clear overview of the topic as well as the author's expert opinion.***

02916557

I found the manuscript interesting. However, some aspects of the manuscript have to be improved. There are minor language polishing.

The author has edited the manuscript again for any language issues, and included the suggestions given above.

Thanks again.